Dynamic metabolic changes during the first 3 months after 90Y-ibritumomab tiuxetan radioimmunotherapy.

about

Dynamic metabolic changes during the first 3 months after 90Y-ibritumomab tiuxetan radioimmunotherapy.

Item

http://www.wikidata.org/entity/Q53059192

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Dynamic metabolic changes duri ...... b tiuxetan radioimmunotherapy.

@en

Dynamic metabolic changes duri ...... b tiuxetan radioimmunotherapy.

@nl

type

Item

label

Dynamic metabolic changes duri ...... b tiuxetan radioimmunotherapy.

@en

Dynamic metabolic changes duri ...... b tiuxetan radioimmunotherapy.

@nl

prefLabel

Dynamic metabolic changes duri ...... b tiuxetan radioimmunotherapy.

@en

Dynamic metabolic changes duri ...... b tiuxetan radioimmunotherapy.

@nl

P1476

Dynamic metabolic changes duri ...... ab tiuxetan radioimmunotherapy

@en

P2093

Keitaro Koyama

http://www.w3.org/2001/XMLSchema#string

Kuni Ohtomo

http://www.w3.org/2001/XMLSchema#string

Mineo Kurokawa

http://www.w3.org/2001/XMLSchema#string

P2860

Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody.

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Arming antibodies for cancer therapy.

Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.

Imaging pharmacodynamics in oncology: the potential significance of "flares".

Assessment of metabolic response to radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma.

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.

Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan.

Role of [18F]-FDG-PET/MDCT in evaluating early response in patients with Hodgkin's lymphoma.

P304

368947

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2014/368947

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

2014

http://www.w3.org/2001/XMLSchema#string

P50

Motoshi Ichikawa

Miwako Takahashi

Toshimitsu Momose

P577

2014-06-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264165383

http://www.w3.org/2001/XMLSchema#string

P698

25050390

http://www.w3.org/2001/XMLSchema#string

P932

4090517

http://www.w3.org/2001/XMLSchema#string